Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Rhea-AI Summary

Allurion Technologies (NYSE: ALUR) has published a study showing impressive weight loss results with its Allurion Program. 486 patients achieved an average weight reduction of 10.5% at four months, improving to 13.7% at one year. The program combines the Allurion Balloon with virtual guidance and support, including monthly assessments using the Allurion App, Connected Scale, and Health Tracker.

Patients had virtual access to registered dieticians, with weekly check-ups in the first month, biweekly for three months, and monthly for the remaining eight months. This approach contrasts with GLP-1 drugs, where patients typically regain about two-thirds of lost weight after discontinuing treatment and lifestyle intervention.

Positive

• Average weight reduction improved from 10.5% at 4 months to 13.7% at 1 year
• Study demonstrates continued weight loss after balloon passage with virtual support
• Largest study of its kind in Southeast Asia for the Allurion Balloon
• Allurion Program shows potential for maintaining and increasing weight loss over time

Negative

• None.

Medical Research Analyst

This study on the Allurion Program presents significant findings for obesity treatment. The 13.7% average weight reduction at one year, improving from 10.5% at four months, is impressive. It's particularly noteworthy that weight loss continued after balloon passage, highlighting the effectiveness of the program's virtual support system. This contrasts with GLP-1 therapies, where patients typically regain about two-thirds of lost weight after discontinuation. The long-term efficacy demonstrated here could position Allurion as a competitive alternative in the obesity treatment market, potentially challenging pharmaceutical approaches. However, we need more comparative studies to fully assess its standing against other treatments.

Financial Analyst

This study could have positive implications for Allurion's market position and financial outlook. The demonstrated long-term efficacy of their program may lead to increased adoption and potentially higher revenue streams. The contrast with GLP-1 therapies' weight regain issues could give Allurion a competitive edge in the lucrative obesity treatment market. However, investors should note that this is a single-center study and broader, multi-center trials would further solidify these findings. The company's NYSE listing (ALUR) suggests it's positioned for growth, but as with any medical technology, regulatory approvals and market acceptance will be important for long-term success.

Market Research Analyst

The Allurion Program's results present a compelling value proposition in the obesity treatment market. The combination of a physical intervention (the balloon) with long-term virtual support addresses two critical aspects of weight loss: initial reduction and maintenance. This holistic approach could resonate well with consumers seeking sustainable solutions. The virtual nature of the follow-up program aligns with current healthcare trends, potentially increasing accessibility and adherence. However, the market will need to weigh this against the convenience of oral medications like GLP-1 agonists. Allurion's success will likely depend on effective marketing to highlight its unique benefits and potentially lower long-term costs compared to ongoing medication use.

Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program

Separate studies with patients on GLP-1 therapy report significant weight re-gain after discontinuation of drug and lifestyle intervention program

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average weight reduction of 10.5% at four months on the Allurion Program, improving to 13.7% at one year. This data indicate that weight loss can not only be maintained by utilizing the Allurion Program, but it can also be increased by taking advantage of the Program’s ongoing virtual guidance and support.

In the study, 486 patients at a single, high-volume bariatric center were treated with the Allurion Balloon and assessed monthly with the Allurion App, Connected Scale, and Health Tracker as part of the Allurion Program. Over one year, participants were given virtual access to a team of registered dieticians. A weekly check-up was conducted for the first month, followed by biweekly check-ups for the subsequent three months, and monthly check-ups for the remaining eight months.

"This study is the largest of its kind in Southeast Asia since the Allurion Balloon was introduced in the region. Results demonstrate that the swallowable gastric balloon is an effective solution for patients seeking to lose weight and keep that weight off,” said Dr. Nik Ritza Kosai, Associate Professor and Consultant in Gastrointestinal, Obesity and Metabolic Surgery at The National University of Malaysia and lead author of the study. “Furthermore, our findings offer strong evidence that the combination of balloon intervention and one year of virtual supervision can significantly augment weight loss outcomes.”

Previous studies evaluating GLP-1 drugs indicate that after discontinuation of the drug and lifestyle intervention program, patients regained approximately two-thirds of the weight they had lost.^1-3

“While most weight loss is typically observed within the first four months on the Allurion Program while the balloon is in residence, the findings from this study demonstrate that, for these patients, the combination of the Allurion Balloon with a 12-month, structured, virtual support program significantly contributed to improved weight loss after balloon passage,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We believe this study validates our approach of combining the Allurion Balloon with systematic evaluation, monitoring, and guidance, offering a more effective pathway to achieving and maintaining successful weight loss outcomes.”

Sources: 1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. 2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. 3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Program, which combines the Allurion Balloon with ongoing virtual guidance and support, to improve patient and clinical outcomes, including outcome improvements over time. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828124974/en/

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com

Investor Contact

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.

FAQ

What were the weight loss results in the Allurion Program study?

The study showed an average weight reduction of 10.5% at four months, improving to 13.7% at one year for 486 patients on the Allurion Program.

How does the Allurion Program (ALUR) compare to GLP-1 drugs for weight maintenance?

Unlike GLP-1 drugs where patients regain about two-thirds of lost weight after discontinuation, the Allurion Program demonstrated continued weight loss even after balloon passage with ongoing virtual support.

What components are included in the Allurion Program for weight loss?

The Allurion Program includes the Allurion Balloon, Allurion App, Connected Scale, Health Tracker, and virtual access to registered dieticians for ongoing guidance and support.

How long does the virtual support last in the Allurion Program study?

The study provided virtual support for one year, with weekly check-ups in the first month, biweekly for three months, and monthly for the remaining eight months.